QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical...
Read moreLatest News
Category: News
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
Telix today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure...
Read more
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
Telix today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics...
Read more
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
Telix today announces its financial results for the financial year ended 31 December 2023....
Read more
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
Telix today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.)...
Read more
Telix Full Year Results 2023 Investor Webcast Notification
Telix today advises that it will release its full year results and Annual Report for the period ended 31 December 2023 on Thursday 22 February...
Read more
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
Telix today announces presentations featuring the Company’s theranostic programs at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA...
Read more
Presentation to J.P. Morgan Healthcare Conference and Q4 Revenue Update
Telix today advises it is presenting at the 42nd Annual J.P. Morgan Healthcare Conference (8-11 January 2024) in San...
Read more
Appointment of Dr David Cade to Group Chief Medical Officer
Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging...
Read more
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational positron emission tomography (PET) imaging...
Read more